Max Healthcare Institute Ltd Q1 FY27 Results

Max Healthcare faces a quarter pulled by two opposing forces. On the upside: easier base (Q1 FY-2026 was affected by COVID), CGHS rate revisions now in place, and bed additions ramping at flagship Noida and Dwarka units. On the headwind: Delhi market report of softening occupancy and slower admissions in Q1 2026, a dynamic that typically pressures both volume and mix. The Street narrative pivots on whether the company can hold margins despite the slowdown—or if a shift to lower-acuity patients and discount-driven competition erodes the 38-40% EBITDA run-rate. Price at ₹1,040 sits below both 50-day and 200-day SMAs, a posture that suggests caution going in.

Strong: Revenue beats ₹2,750+ Cr on faster occupancy recovery + mix recovery toward higher-margin critical care. EBITDA margin stays above 39%, showing pricing power despite Delhi softness. Guidance reaffirms FY27 growth momentum. PAT of ₹350 Cr+, with management commentary on pipeline visibility into H2. Weak: Revenue below ₹2,600 Cr on persistent Delhi slowdown. EBITDA margin compresses to sub-38%, signaling either pricing pressure or mix shift into lower-margin routine care. Management signals caution on occupancy for H2 or pushes out bed addition timeline. PAT below ₹300 Cr, triggering analyst target cuts.

Max had guided for mid-to-high single-digit organic growth for FY27, anchored on ramp-up of 600+ beds added across Noida, Dwarka, and Delhi facilities. A ~10% Q1 result would be in-line with that trajectory, but the Delhi softness is the swing variable. If the slowdown persists into Q2–Q3, FY27 guidance could come under pressure. Positively, the property acquisition (Yerawada in Pune, 50.22% stake, June 2026) signals management confidence in real-estate value creation alongside ops, and the CCI ruling (May 2026) closed a key risk around pricing power. Bed capacity pipeline remains intact: Lucknow Phase-I (712 beds, board-approved) and Dwarka unit ramp-ups are both on schedule. The test is whether operations can scale ahead of capacity dilution from pricing competition.

Max delivered revenue guidance (16.7% YoY) but near-term profitability softened by new brownfield capacity absorption, oncology drag, and working capital buildup (AR +₹250 Cr YoY). Long-term case intact: 3000+ bed pipeline, medical education entry (₹300 Cr capex, 25-30% ROCE), ARPOB growth above inflation. Key risk: execution speed on massive capex amid Parliamentary Committee scrutiny on sector viability.

Q&A was respectful but probing. Analysts pressed on oncology magnitude (Max vs peers), CGHS profitability, insurance company pressure on admissions, capex opex absorption, and free cash flow bridge. MD and CFO addressed most with data (occupancy ramp trajectories, insurance regulation deference to doctors, cost timing logic). Some evasion: declined to reinstate regional disclosure (competitive sensitivity with single-hospital states). Overall: confident, transparent on headwinds, held under pressure.

Score 8/10. Transparent on challenges (oncology drag, AR buildup, cost absorption in new hospitals). No hype; anchors claims in playbook precedent (Lucknow, Noida). Declines to speculate; grounds answers in data. On track: revenue +16.7% vs 16% guided; capacity ramp (Smart 80%, Nanavati 80%) as planned. Acquisition integration (Kalinga) within 12-month timeline. Free cash flow 56% conversion vs 62-65% target; blames temporary AR buildup, credible.

Max Healthcare's consolidated revenue for Q1 FY27 (quarter ended June 30, 2026) rose 16.7% YoY and 10.4% QoQ to ₹2,366 Cr (₹2,407 Cr total income), while consolidated PAT (profit for the period) grew a much slower 4.9% YoY and fell 5.6% QoQ to ₹322.96 Cr — of which ₹322.49 Cr accrued to owners after a newly-arisen ₹0.47 Cr minority interest tied to the Kalinga Hospital acquisition. Basic EPS was ₹3.32, against ₹3.17 a year ago and ₹3.52 in the prior quarter. No reliable street/consensus estimate for this specific print could be confirmed via search, so vs-street is left unassessed rather than guessed.

The gap between revenue and profit growth is a margin story: OPM (EBITDA margin) slipped to 25.3% from 25.8% YoY and from 28.3% QoQ, and NPM fell to 13.4% from 14.9% YoY and 15.6% QoQ. Finance costs rose 29% YoY to ₹71.0 Cr and depreciation rose 26% YoY to ₹131.7 Cr, both inflated by the ECB drawn to fund the ₹298 Cr Kalinga Hospital acquisition (58.28% stake, consolidated from May 18, 2026) and ongoing capacity build-out. This lines up with management's prior-quarter guidance, which explicitly flagged near-term EBITDA drag from newly commissioned/acquired capacity before full operating leverage shows up as occupancy ramps — so the margin dip looks like guided-for integration cost, not a surprise miss against what management said.

The stock went into the print at ₹1,020.3, down 7.5% over the past month of trading.

For context: revenue is at a 6-quarter high.

Standalone (parent-only) numbers show a starker divergence: standalone PAT was nearly flat YoY at ₹167.6 Cr (+0.9%) on revenue of ₹782.9 Cr (+12.8% YoY), confirming most of the consolidated growth is coming from subsidiaries and newly consolidated hospitals rather than the core standalone entity. Network-wide capacity utilisation was above 75% in the quarter on an existing base of 6,100+ beds. The same board meeting approved ₹425 Cr of capex for a new 'Tower 3' block (~250 beds) at Max Super Speciality Hospital, Vaishali, commissioning by November 2029, plus an in-principle approval to explore setting up medical colleges. There were no exceptional items this quarter on either basis, unlike FY26's full year, which carried ₹48.2 Cr of labour-code and merger stamp-duty exceptional charges — so this YoY comparison is clean on both sides. No separate management press release accompanies this filing beyond the board-outcome letter, so there is no additional management framing to reconcile against the numbers.